<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">19066855</PMID>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-2072</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>203</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychopharmacology</Title>
                <ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>723-35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-008-1419-x</ELocationID>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Prepulse inhibition (PPI) is an operational measure of sensorimotor gating that is deficient in schizophrenia patients. In rats, PPI deficits induced by dopamine (DA) agonists are reversed by antipsychotics. Inhibition of the striatum-rich phosphodiesterase (PDE)10A may represent a novel antipsychotic mechanism. Previous studies were controversial, showing antipsychotic-like profiles in measures of PPI for the preferential PDE10A inhibitor papaverine (PAP) but not the novel PDE10A inhibitor TP-10.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to evaluate the antipsychotic profile of PAP in rats using PPI.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">PPI deficits were induced in rats by apomorphine (APO; 0.1, 0.5 mg/kg) or D: -amphetamine (AMPH; 4 mg/kg). PAP (3, 10, 30 mg/kg) or haloperidol (HAL; 0.1 mg/kg) was tested against these agonists in Sprague-Dawley (SD) or Wistar (WI) rats. Prepulse intervals ranged from 10 to 120 ms. Further tests evaluated the effects of PAP on spontaneous locomotion, AMPH (1 mg/kg)-induced hyperlocomotion, and core body temperature (T degrees ).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">HAL reversed APO-induced PPI deficits but PAP failed to reverse APO- and AMPH-induced PPI deficits at all doses, strains, pretreatment times, and prepulse intervals. PAP (30 mg/kg) significantly reduced AMPH hyperlocomotion in SD rats, and a similar pattern was detected in WI rats. This PAP dose also strongly reduced spontaneous locomotion and T degrees in SD rats.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study does not support an antipsychotic-like profile of PAP in dopaminergic PPI models.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0804, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breier</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thangaraj</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marzan</LastName>
                    <ForeName>D E</ForeName>
                    <Initials>DE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swerdlow</LastName>
                    <ForeName>N R</ForeName>
                    <Initials>NR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 MH068366</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH068366-05A2</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Psychopharmacology (Berl)</MedlineTA>
            <NlmUniqueID>7608025</NlmUniqueID>
            <ISSNLinking>0033-3158</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CK833KGX7E</RegistryNumber>
                <NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DAA13NKG2Q</RegistryNumber>
                <NameOfSubstance UI="D010208">Papaverine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.4.-</RegistryNumber>
                <NameOfSubstance UI="C512064">PDE10A protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.4.-</RegistryNumber>
                <NameOfSubstance UI="D010727">Phosphoric Diester Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N21FAR7B4S</RegistryNumber>
                <NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010208" MajorTopicYN="N">Papaverine</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010727" MajorTopicYN="N">Phosphoric Diester Hydrolases</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>08</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19066855</ArticleId>
            <ArticleId IdType="doi">10.1007/s00213-008-1419-x</ArticleId>
            <ArticleId IdType="pmc">PMC2748940</ArticleId>
            <ArticleId IdType="mid">NIHMS119431</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Pharmacol Biochem Behav. 2005 Oct;82(2):293-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16188305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 2005 Sep;42(5):588-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16176381</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuroscience. 2006 May 12;139(2):597-607</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16483723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropharmacology. 2006 Aug;51(2):386-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16780899</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuroscience. 2007 Jan 5;144(1):239-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17081698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Schizophr Bull. 2007 Jan;33(1):69-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17135482</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2007 Mar;32(3):577-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16738544</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2007 May;32(5):1021-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17047669</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Discov Today. 2007 Oct;12(19-20):870-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17933689</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2008 Mar;197(1):115-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18060387</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Psychiatry. 2008 Apr 15;63(8):748-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18083141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2008 May;325(2):681-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18287214</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2008 Jul;326(1):230-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18420599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2008 Aug;199(3):331-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18568339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neurosci. 2008 Oct 15;28(42):10460-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18923023</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Brain Res. 2007 Aug 22;182(1):1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17570538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neurosci. 2000 Jun 1;20(11):4325-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10818168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Psychiatry. 2000 Oct;157(10):1660-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11007721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11549216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11549226</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2003 Feb;28(2):226-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12589375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12668349</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Brain Res. 2003 Sep 26;985(2):113-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12967715</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 2004 Aug;174(4):452-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15300359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2004 Oct;29(10):1823-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15138441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychiatr Neurol Neurochir. 1972 May-Jun;75(3):193-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4625013</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 1975 May;12(3):238-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1153628</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychophysiology. 1978 Jul;15(4):339-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">693742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 1982;77(4):309-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6182575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychopharmacology (Berl). 1988;94(4):507-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3131796</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Psychiatry. 1991 Oct;148(10):1301-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1654746</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Gen Psychiatry. 1994 Feb;51(2):139-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8297213</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1994 Sep 16;269(37):23120-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7916015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 1998 Jan;18(1):50-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9408918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Behav Pharmacol. 1998 Sep;9(5-6):445-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9832930</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1999 Jun 25;274(26):18438-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10373451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2005 Sep 22;353(12):1209-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16172203</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropsychopharmacology. 2006 Apr;31(4):721-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16123742</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
